ReachMD CME-logo

ReachMD CME

ReachMD

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women's health and more. And our CME library is continuously growing, every quarter.

Location:

Fort Washington, PA

Networks:

ReachMD

Description:

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women's health and more. And our CME library is continuously growing, every quarter.

Language:

English


Episodes

Revolutionizing Care for Patients With T2D and Obesity: From Pathophysiology to Personalized Treatments

2/20/2024
CME credits: 0.50 Valid until: 20-02-2025 Claim your CME credit at https://reachmd.com/programs/cme/revolutionizing-care-for-patients-with-t2d-and-obesity-from-pathophysiology-to-personalized-treatments/16467/ Embark on a transformative journey to redefine patient care for individuals with type 2 diabetes by transitioning from the conventional focus on glycemic control to a pioneering obesity-centered approach. Immerse yourself in the expertise of 3 distinguished professionals: Drs. Carol Wysham, Scott Kahan, and Ken Fujioka. These esteemed experts will guide you through the dynamic terrain of weight loss medications, including GLP-1/GIP dual receptor agonists, and provide invaluable insights to elevate and optimize patient outcomes in the realm of type 2 diabetes management.

Duration:00:22:29

Patient-Centric Approaches to Managing Migraines in the Female Patient

2/13/2024
CME credits: 0.25 Valid until: 13-02-2025 Claim your CME credit at https://reachmd.com/programs/cme/patient-centric-approaches-to-managing-migraines-in-the-female-patient/16281/ Half of the women in the US with migraine are never diagnosed. Of those who are, the journey to effective treatment may last a decade or longer. But newer and more effective targeted treatments are beginning to make a difference. Join Drs. Jessica Ailani and Dawn Buse as they discuss a novel approach to managing migraine and interview a patient whose migraine journey is unfortunately one traversed by many women.

Duration:00:14:30

Migraine: Clinical Approaches and a Patient’s Perspective

2/13/2024
CME credits: 0.25 Valid until: 13-02-2025 Claim your CME credit at https://reachmd.com/programs/cme/migraine-clinical-approaches-and-a-patients-perspective/16281/ Half of the women in the US with migraine are never diagnosed. Of those who are, the journey to effective treatment may last a decade or longer. But newer and more effective targeted treatments are beginning to make a difference. Join Drs. Jessica Ailani and Dawn Buse as they discuss a novel approach to managing migraine and interview a patient whose migraine journey is unfortunately one traversed by many women.

Duration:00:14:30

Migraine and Women’s Health: Migraine and the Whole Female Patient

2/13/2024
CME credits: 0.25 Valid until: 13-02-2025 Claim your CME credit at https://reachmd.com/programs/cme/migraine-and-womens-health-migraine-and-the-whole-female-patient/16281/ Half of the women in the US with migraine are never diagnosed. Of those who are, the journey to effective treatment may last a decade or longer. But newer and more effective targeted treatments are beginning to make a difference. Join Drs. Jessica Ailani and Dawn Buse as they discuss a novel approach to managing migraine and interview a patient whose migraine journey is unfortunately one traversed by many women.

Duration:00:14:30

Expert Answers to Common Questions on Response Matters: Transforming the Standard of Care in CML by Mastering Response-Guided Treatment

2/13/2024
CME credits: 0.25 Valid until: 12-02-2025 Claim your CME credit at https://reachmd.com/programs/cme/expert-answers-to-common-questions-on-response-matters-transforming-the-standard-of-care-in-cml-by-mastering-response-guided-treatment/15663/ Chronic myeloid leukemia is a myeloproliferative neoplasm characterized by disordered growth of myeloid cells. The hallmark of chronic myeloid leukemia (CML) is an acquired reciprocal translocation between the long arms of chromosomes 9 and 22. This translocation results in the BCR-ABL1 fusion protein, with constitutively active tyrosine kinase activity, and is the underlying driver of CML. BCR-ABL1 testing is widely used to confirm the clinical diagnosis of CML and to assess response to TKI therapy. The development of BCR-ABL1 tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of CML, dramatically improving patient outcomes. Although most CML patients experience excellent clinical outcomes, some CML patients (20-30%) exhibit an acquired resistance to treatment during the disease course, often requiring second- or third-line therapy. Novel TKIs designed to overcome TKI resistance have shown efficacy in early clinical trials and are offering promise to CML patients who do not respond to any of the multiple therapeutic options currently available. AXIS routinely collects and analyzes data gathered from participants in our live activities. These questions and answers provide incredible insight and address genetic testing, risk stratification, disease stages, and optimal treatment for patients with CML. This includes a focus on the clinical significance of BCR-ABL …

Duration:00:12:59

Unlocking the Potential of HER2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches

2/9/2024
CME credits: 0.25 Valid until: 28-02-2025 Claim your CME credit at https://reachmd.com/programs/cme/unlocking-the-potential-of-her2-targeted-therapy-breakthroughs-in-nsclc-therapeutic-approaches/16213/ Dr. Helena Yu of Memorial Sloan Kettering Cancer Center presents an insightful overview of HER2 targeted therapy in non-small cell lung cancer (NSCLC), emphasizing the critical role of broad molecular profiling in ensuring effective treatment, particularly for the 2-4% of NSCLC patients with HER2 mutations. Dr. Yu highlights the effectiveness of newer antibody–drug conjugates (ADCs) such as trastuzumab deruxtecan (T-DXd) for NSCLC with HER2 mutations, while also detailing identification and management of potential side effects. Through a patient engagement vignette, she underscores the importance of aligning treatment choices with patient and clinician goals, highlighting shared decision-making in managing HER2-mutant NSCLC.

Duration:00:11:29

Expert Answers to Common Questions for Tailoring ADC Therapies Across the HER2 Spectrum in Metastatic Breast Cancer

2/6/2024
CME credits: 0.25 Valid until: 05-02-2025 Claim your CME credit at https://reachmd.com/programs/cme/expert-answers-to-common-questions-for-tailoring-adc-therapies-across-the-her2-spectrum-in-metastatic-breast-cancer/15658/ HER2 is a well-established negative prognostic factor for metastatic breast cancer (mBC) and determining HER2 levels is essential for proper treatment decisions. Several studies have reported scoring inaccuracies for HER2 status, particularly in the low range (0 and 1+), and challenges with IHC assessment and interpretation can lead to the misassignment of many patients for treatment. Antibody-drug conjugates (ADCs), a new and promising class of therapeutics designed as targeted therapy for mBC, target and kill tumor cells while sparing healthy cells. Rapid advances in ADC development are transforming HER2-positive and HER2-low mBC patient outcomes. With recent FDA approvals of HER2-targeting agents and emerging positive trial data, clinicians and pathologists are faced with staying abreast of and integrating new treatment options into real-world clinical practice. AXIS routinely collects and analyzes data gathered from participants in our live activities. These questions and answers provide incredible insight regarding testing methodologies to classify metastatic breast cancer according to HER2 status, addressing the strengths and limitations of different techniques. The clinical implications of these tests for guiding HER2-targeted therapies such as antibody-drug conjugates will be addressed, as well as evidence-based methods to address challenges such as treatment-associated adverse events and drug resistance, and key messages …

Duration:00:13:59

Incorporating Data Into Practice: Late-Breaking Highlights on G/GEJ Cancers From the 2024 GI Congress

2/5/2024
CME credits: 1.00 Valid until: 05-02-2025 Claim your CME credit at https://reachmd.com/programs/cme/incorporating-data-into-practice-late-breaking-highlights-on-ggej-cancers-from-the-2024-gi-congress/18028/ The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regarding first-line treatments for advanced or metastatic G/GEJ cancers and the differentiation between HER2-positive and -negative tumors. In addition to HER2, Claudin 18 splice variant 2 (CLDN18.2) has emerged as a new biomarker for targeted treatment. Multiple factors should be considered in first-line treatment selection, including biomarker positivity, performance status, and potential toxicity. In this program, topics presented by expert faculty will illustrate the biomarker-related clinicopathologic features of G/GEJ cancers as well as how to incorporate the latest evidence to individualize first-line treatment for patients with G/GEJ cancers. Please stay tuned for additional content to this program available for credit. MedEd On The Go will track the episodes you watch and provide you with the option to claim credit once you have reached the level of participation needed in order to claim. The maximum amount of credits available for the entire activity is 1.25.

Duration:00:05:59

What Is the Evidence Supporting CLDN18.2 Targeting in Frontline Management of G/GEJ Cancers

2/5/2024
CME credits: 1.00 Valid until: 05-02-2025 Claim your CME credit at https://reachmd.com/programs/cme/what-is-the-evidence-supporting-cldn182-targeting-in-frontline-management-of-ggej-cancers/18027/ The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regarding first-line treatments for advanced or metastatic G/GEJ cancers and the differentiation between HER2-positive and -negative tumors. In addition to HER2, Claudin 18 splice variant 2 (CLDN18.2) has emerged as a new biomarker for targeted treatment. Multiple factors should be considered in first-line treatment selection, including biomarker positivity, performance status, and potential toxicity. In this program, topics presented by expert faculty will illustrate the biomarker-related clinicopathologic features of G/GEJ cancers as well as how to incorporate the latest evidence to individualize first-line treatment for patients with G/GEJ cancers. Please stay tuned for additional content to this program available for credit. MedEd On The Go will track the episodes you watch and provide you with the option to claim credit once you have reached the level of participation needed in order to claim. The maximum amount of credits available for the entire activity is 1.25.

Duration:00:05:59

What Is the Current Standard for First-Line Treatment of Metastatic HER2-Positive G/GEJ Cancers?

2/5/2024
CME credits: 1.00 Valid until: 05-02-2025 Claim your CME credit at https://reachmd.com/programs/cme/what-is-the-current-standard-for-first-line-treatment-of-metastatic-her2-positive-ggej-cancers/18026/ The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regarding first-line treatments for advanced or metastatic G/GEJ cancers and the differentiation between HER2-positive and -negative tumors. In addition to HER2, Claudin 18 splice variant 2 (CLDN18.2) has emerged as a new biomarker for targeted treatment. Multiple factors should be considered in first-line treatment selection, including biomarker positivity, performance status, and potential toxicity. In this program, topics presented by expert faculty will illustrate the biomarker-related clinicopathologic features of G/GEJ cancers as well as how to incorporate the latest evidence to individualize first-line treatment for patients with G/GEJ cancers. Please stay tuned for additional content to this program available for credit. MedEd On The Go will track the episodes you watch and provide you with the option to claim credit once you have reached the level of participation needed in order to claim. The maximum amount of credits available for the entire activity is 1.25.

Duration:00:06:00

What Is the Current Standard for First-Line Treatment of Metastatic HER2-Negative G/GEJ Cancers?

2/5/2024
CME credits: 1.00 Valid until: 05-02-2025 Claim your CME credit at https://reachmd.com/programs/cme/what-is-the-current-standard-for-first-line-treatment-of-metastatic-her2-negative-ggej-cancers/18025/ The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regarding first-line treatments for advanced or metastatic G/GEJ cancers and the differentiation between HER2-positive and -negative tumors. In addition to HER2, Claudin 18 splice variant 2 (CLDN18.2) has emerged as a new biomarker for targeted treatment. Multiple factors should be considered in first-line treatment selection, including biomarker positivity, performance status, and potential toxicity. In this program, topics presented by expert faculty will illustrate the biomarker-related clinicopathologic features of G/GEJ cancers as well as how to incorporate the latest evidence to individualize first-line treatment for patients with G/GEJ cancers. Please stay tuned for additional content to this program available for credit. MedEd On The Go will track the episodes you watch and provide you with the option to claim credit once you have reached the level of participation needed in order to claim. The maximum amount of credits available for the entire activity is 1.25.

Duration:00:06:00

Claudin18.2: An Emerging Biomarker and Its Significance as a Therapeutic Target in G/GEJ Cancers

2/5/2024
CME credits: 1.00 Valid until: 05-02-2025 Claim your CME credit at https://reachmd.com/programs/cme/claudin182-an-emerging-biomarker-and-its-significance-as-a-therapeutic-target-in-ggej-cancers/18024/ The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regarding first-line treatments for advanced or metastatic G/GEJ cancers and the differentiation between HER2-positive and -negative tumors. In addition to HER2, Claudin 18 splice variant 2 (CLDN18.2) has emerged as a new biomarker for targeted treatment. Multiple factors should be considered in first-line treatment selection, including biomarker positivity, performance status, and potential toxicity. In this program, topics presented by expert faculty will illustrate the biomarker-related clinicopathologic features of G/GEJ cancers as well as how to incorporate the latest evidence to individualize first-line treatment for patients with G/GEJ cancers. Please stay tuned for additional content to this program available for credit. MedEd On The Go will track the episodes you watch and provide you with the option to claim credit once you have reached the level of participation needed in order to claim. The maximum amount of credits available for the entire activity is 1.25.

Duration:00:05:59

HER2 & PD-L1: Exploring Clinical Characteristics of G/GEJ Cancers in Relation to Biomarker Positivity

2/5/2024
CME credits: 1.00 Valid until: 05-02-2025 Claim your CME credit at https://reachmd.com/programs/cme/her2-pd-l1-exploring-clinical-characteristics-of-ggej-cancers-in-relation-to-biomarker-positivity/18023/ The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regarding first-line treatments for advanced or metastatic G/GEJ cancers and the differentiation between HER2-positive and -negative tumors. In addition to HER2, Claudin 18 splice variant 2 (CLDN18.2) has emerged as a new biomarker for targeted treatment. Multiple factors should be considered in first-line treatment selection, including biomarker positivity, performance status, and potential toxicity. In this program, topics presented by expert faculty will illustrate the biomarker-related clinicopathologic features of G/GEJ cancers as well as how to incorporate the latest evidence to individualize first-line treatment for patients with G/GEJ cancers. Please stay tuned for additional content to this program available for credit. MedEd On The Go will track the episodes you watch and provide you with the option to claim credit once you have reached the level of participation needed in order to claim. The maximum amount of credits available for the entire activity is 1.25.

Duration:00:05:59

Systemic Gout Uncovered: Primary Care Perspectives and Solutions

2/2/2024
CME credits: 0.50 Valid until: 02-02-2025 Claim your CME credit at https://reachmd.com/programs/cme/systemic-gout-uncovered-primary-care-perspectives-and-solutions/16194/ Many patients with gout don’t achieve their target urate levels with conventional urate-lowering therapies. Join renowned experts Drs. Xu He and John Botson as they dissect the potential benefits of urate reduction, discuss management options for patients with uncontrolled gout, and underscore the critical significance of timely referrals from primary care to specialty care in optimizing outcomes for patients with uncontrolled gout.

Duration:00:27:04

Putting Data into Clinical Practice

1/31/2024
CME credits: 0.50 Valid until: 24-01-2025 Claim your CME credit at https://reachmd.com/programs/cme/putting-data-into-clinical-practice/17847/ The Changing TAVR Landscape" is a comprehensive multiepisodic CME series addressing critical aspects of the evolving transcatheter aortic valve replacement (TAVR) landscape. Join our experts as they discuss topics on patient identification ranging from the use of echocardiography to identify symptomatic severe aortic stenosis patients to challenging case discussions, device durability, and up-to-date clinical trial data.

Duration:00:05:30

New TAVR Data – New TAVR Talk Track

1/31/2024
CME credits: 0.50 Valid until: 24-01-2025 Claim your CME credit at https://reachmd.com/programs/cme/new-tavr-data-new-tavr-talk-track/17846/ The Changing TAVR Landscape" is a comprehensive multiepisodic CME series addressing critical aspects of the evolving transcatheter aortic valve replacement (TAVR) landscape. Join our experts as they discuss topics on patient identification ranging from the use of echocardiography to identify symptomatic severe aortic stenosis patients to challenging case discussions, device durability, and up-to-date clinical trial data.

Duration:00:05:30

Challenging TAVR Cases

1/31/2024
CME credits: 0.50 Valid until: 24-01-2025 Claim your CME credit at https://reachmd.com/programs/cme/challenging-tavr-cases/17845/ The Changing TAVR Landscape" is a comprehensive multiepisodic CME series addressing critical aspects of the evolving transcatheter aortic valve replacement (TAVR) landscape. Join our experts as they discuss topics on patient identification ranging from the use of echocardiography to identify symptomatic severe aortic stenosis patients to challenging case discussions, device durability, and up-to-date clinical trial data.

Duration:00:05:30

It’s All About Patient Identification

1/31/2024
CME credits: 0.50 Valid until: 24-01-2025 Claim your CME credit at https://reachmd.com/programs/cme/its-all-about-patient-identification/17844/ The Changing TAVR Landscape" is a comprehensive multiepisodic CME series addressing critical aspects of the evolving transcatheter aortic valve replacement (TAVR) landscape. Join our experts as they discuss topics on patient identification ranging from the use of echocardiography to identify symptomatic severe aortic stenosis patients to challenging case discussions, device durability, and up-to-date clinical trial data.

Duration:00:04:00

Is Amyloid-Targeting Therapy Worth It?

1/31/2024
CME credits: 1.25 Valid until: 31-01-2025 Claim your CME credit at https://reachmd.com/programs/cme/is-amyloid-targeting-therapy-worth-it/16466/ Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD. Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise

Duration:00:03:42

Do Women Respond Differently to ATT Than Men?

1/31/2024
CME credits: 1.25 Valid until: 31-01-2025 Claim your CME credit at https://reachmd.com/programs/cme/do-women-respond-differently-to-att-than-men/16344/ Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD. Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise

Duration:00:03:28